Efficacy and Safety of Botulinum Toxin at Moderate to Severe Glabellar Lines
NCT ID: NCT04830345
Last Updated: 2022-04-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
290 participants
INTERVENTIONAL
2020-06-29
2021-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Comparative Study of Botulinum Neurotoxin Type A in Treatment of Moderate to Severe Glabellar Frown Lines
NCT04281095
Safety and Efficacy Study of Botulinum Toxin Type A to Treat Glabellar Lines
NCT01485601
Efficacy and Safety Assessment of Botulax® and BOTOX® for Improvement of Glabellar Lines.
NCT05380154
Evaluate the Safety and Efficacy of HG102 as Compared to Botox® in Subject With Moderate to Severe Glabellar Lines
NCT05801146
Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) in Korea
NCT02043145
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ATGC-100 100U
ATGC-100 will be injected to 5 glabellar lines (each 4U/0.1mL; total 20U) at Day 0
ATGC-100 100U
Clostridium botulinum toxin type A
Botox 100U
Botox inj. will be injected to 5 glabellar lines (each 4U/0.1mL; total 20U) at Day 0
Botox 100U
Clostridium botulinum toxin type A
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ATGC-100 100U
Clostridium botulinum toxin type A
Botox 100U
Clostridium botulinum toxin type A
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Participants with Facial Wrinkle Scale (FWS) score of \> 2 at maximum frown at screening
3. Participants willing to follow the study procedures and schedules
4. Participants willing to give written informed consent to participate in the trial
Exclusion Criteria
2. Pregnant, lactating women or women of childbearing age not using a reliable method of contraception
3. Participants with known hypersensitivity to any component of the study drug
4. Participant who has skin disorder including infection and scar on injection site
19 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
EuBiologics Co.,Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nowon Eulji University Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CBA-PLN-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.